Neogenix Oncology announced today that Dr. Luis Diaz of The Johns Hopkins University Hospital will present data from Ensituximab, the company's novel, therapeutic antibody to treat pancreatic and colorectal cancers. The presentation is scheduled at the American Society of Clinical Oncology (ASCO) 2011 Gastrointestinal Cancers Symposium to be held January 20-22, 2011 at the Moscone Center in San Francisco, CA, USA.
“There is a serious need for new therapies for life-threatening cancers, especially pancreatic cancer where very few treatment options exist. We are pleased to be working with the investigators at these prestigious medical establishments for the therapeutic development of Ensituximab”
NPC-1C (Ensituximab) is a chimeric monoclonal antibody being developed as a novel biological treatment for pancreatic and colorectal cancer and is currently in Phase I clinical trials at The Johns Hopkins University Hospital, Duke University Medical Center, and North Shore University/Long Island Jewish Medical Center. Ensituximab is the first of the Neogenix pipeline of antibodies that target specific cancers. The NPC-1C epitope appears to be a variant of MUC5AC that is expressed specifically by human colon and pancreatic tumor tissues and cell lines with only minimal and weak cross-reaction occasionally to certain GI tract tissues. This Phase I open label, multi-center dose escalation clinical trial is currently accruing patients with advanced pancreatic and colorectal cancer who are refractory to standard therapy.
"There is a serious need for new therapies for life-threatening cancers, especially pancreatic cancer where very few treatment options exist. We are pleased to be working with the investigators at these prestigious medical establishments for the therapeutic development of Ensituximab," said Dr. Philip M. Arlen, CEO of Neogenix Oncology.
Poster Presentation Information:
Abstract Title: NPC-1C: A novel, therapeutic antibody to treat pancreas and colorectal cancers.
Poster Session Date/Time: Friday January 21st at 11:45am-1:15pm, and 4:45p-6:00pm.
Permanent Abstract ID: 235
Location: Poster Session B
The full abstract can be accessed through the ASCO GI website http://www.gicasym.org and the Neogenix Oncology website, www.neogenix.com. The complete study presentation poster will also be available on the Neogenix website, following the presentation.
New cancer projections show increased prostate cases by 25% in 2050, despite prevention efforts